Literature DB >> 34305149

Screening and Selection: The Case of Mammograms.

Liran Einav1, Amy Finkelstein2, Tamar Oostrom3, Abigail Ostriker4, Heidi Williams1.   

Abstract

We analyze selection into screening in the context of recommendations that breast cancer screening start at age 40. Combining medical claims with a clinical oncology model, we document that compliers with the recommendation are less likely to have cancer than younger women who select into screening or women who never screen. We show this selection is quantitatively important: shifting the recommendation from age 40 to 45 results in three times as many deaths if compliers were randomly selected than under the estimated patterns of selection. The results highlight the importance of considering characteristics of compliers when making and designing recommendations.

Entities:  

Year:  2020        PMID: 34305149      PMCID: PMC8300583          DOI: 10.1257/aer.20191191

Source DB:  PubMed          Journal:  Am Econ Rev        ISSN: 0002-8282


  56 in total

1.  Greater use of preventive services in U.S. health care could save lives at little or no cost.

Authors:  Michael V Maciosek; Ashley B Coffield; Thomas J Flottemesch; Nichol M Edwards; Leif I Solberg
Journal:  Health Aff (Millwood)       Date:  2010-09       Impact factor: 6.301

Review 2.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

3.  Risk-tailored starting age of breast cancer screening based on women's reproductive profile: A nationwide cohort study.

Authors:  Trasias Mukama; Mahdi Fallah; Yu Tian; Kristina Sundquist; Jan Sundquist; Hermann Brenner; Elham Kharazmi
Journal:  Eur J Cancer       Date:  2019-11-21       Impact factor: 9.162

4.  Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study.

Authors:  Rebecca A Hubbard; Karla Kerlikowske; Chris I Flowers; Bonnie C Yankaskas; Weiwei Zhu; Diana L Miglioretti
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

5.  How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the US Guideline Screening Initiation Ages.

Authors:  Srikanth Kadiyala; Erin Strumpf
Journal:  Forum Health Econ Policy       Date:  2016-06-01

6.  New evidence confirms that reproductive risk factors can be used to stratify breast cancer risks: Implications for a new population screening paradigm.

Authors:  D Gareth Evans; Sacha J Howell; Anthony Howell
Journal:  Eur J Cancer       Date:  2019-11-26       Impact factor: 9.162

7.  Selection on Moral Hazard in Health Insurance.

Authors:  Liran Einav; Amy Finkelstein; Stephen Ryan; Paul Schrimpf; Mark R Cullen
Journal:  Am Econ Rev       Date:  2013-02

8.  The impact of a change in Medicare reimbursement policy and HEDIS measures on stage at diagnosis among Medicare HMO and fee-for-service female breast cancer patients.

Authors:  Elizabeth B Habermann; Beth A Virnig; Gerald F Riley; Nancy N Baxter
Journal:  Med Care       Date:  2007-08       Impact factor: 2.983

9.  The natural history of invasive breast cancers detected by screening mammography.

Authors:  Per-Henrik Zahl; Jan Maehlen; H Gilbert Welch
Journal:  Arch Intern Med       Date:  2008-11-24

10.  Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.

Authors:  Sue M Moss; Howard Cuckle; Andy Evans; Louise Johns; Michael Waller; Lynda Bobrow
Journal:  Lancet       Date:  2006-12-09       Impact factor: 79.321

View more
  2 in total

Review 1.  Health Economics Research in Cancer Screening: Research Opportunities, Challenges, and Future Directions.

Authors:  Ya-Chen Tina Shih; Lindsay M Sabik; Natasha K Stout; Michael T Halpern; Joseph Lipscomb; Scott Ramsey; Debra P Ritzwoller
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

2.  Mammograms and Mortality: How Has the Evidence Evolved?

Authors:  Amanda E Kowalski
Journal:  J Econ Perspect       Date:  2021
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.